Loading...
http://jcps.bjmu.edu.cn

Table of Content

    31 March 2025, Volume 34 Issue 3
    Original articles
    Study on chemical constituents from ethanol extract of Cyclocarya paliurus
    Hailong Xu, Jiao Yang, Tianxia Wang, Gaigai Deng, Youbo Zhang
    2025, 34(3):  195-209.  DOI: 10.5246/jcps.2025.03.015
    Asbtract ( 11 )   HTML ( 2)  
    Figures and Tables | References | Related Articles | Metrics

    The aim of this study is to isolate and identify the chemical compounds in ethanol extract of Cyclocarya paliurus. Some purification and analysis techniques like silica gel, D101-macroporous adsorptive resins, and Sephadex LH-20 column chromatographies as well as high-performance liquid chromatography were used to isolate and analyze the compounds from ethanol extract of Cyclocarya paliurus. The structures of these constituents were identified by spectroscopic techniques such as nuclear magnetic resonance and high-resolution mass spectrometries. Twenty-eight compounds, including flavonoids and their glycoside, carbohydrate, coumarin and organic acid, were isolated from ethyl acetate and n-butanol fractions in ethanol extract of Cyclocarya paliurus, and they were identified as kaempferol (1), coumestrol (2), kaempferol 3-O-β-D-glucoside (3), methyl caffeoylquinic acid (4), coptichic aldehyde (5), schizandriside (6), kaempferol 3-O-α-L-rhamnoside (7), 3-caffeoylquinic acid ethyl ester (8), quercetin (9), luteolin (10), protocatechuic acid (11), kaempferol-3-O-α-L-furan arabinose (12), trans-p-hydroxy-cinnamic acid (13), α-D-glucopyranosido-β-D-fructofuranoside, sucrose (14), peucedanol (15), chlorogenic acid (16), pyridoxine (17), quercetin-3-O-β-D-glucuronide (18), kaempferol-3-O-β-D-glucuronide (19), isoquercitrin (20), mururin A (21), citroside A (22), benzyl-6-O-α-L-arabinofuranosyl-β-D-glucopyranoside (23), (+)-(6S,9R)-9-O-β-D-glucopyranosyl-6-hydroxy-3-O-α-ionol (24), myricetin-3-O-β-D-glucopyranoside (25), (4R)-4-(3-Oxo-1-buten-1-ylidene)-3α,5,5-trimethylcyclohexane-1α,3β-diol (26), quercetin-3-O-α-L-rhamnopyranosyl (27) and 3,5-O-dicaffeoylquinic acid (28). Compounds 2, 5, 6, 15, 21, 22, 23, 24, 26 and 28 were isolated from Cyclocarya paliurus for the first time.

    Synthesis and functional evaluation of low-molecular-weight dextran sulfate as an inhibitor of TGF-β1-induced epithelial-to-mesenchymal transition in A549 cells
    Guohao Song, Linbo Fu, Yidian Mo, Tongtong Geng, Ximin Lv, Xiangbao Meng, Heng Wang, Zhongtang Li, Zhongjun Li
    2025, 34(3):  210-222.  DOI: 10.5246/jcps.2025.03.016
    Asbtract ( 7 )   HTML ( 1)  
    Figures and Tables | References | Related Articles | Metrics

    Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by excessive fibrotic remodeling, for which effective therapeutic options remain severely limited. Among the pathogenic mechanisms implicated in IPF, epithelial-to-mesenchymal transition (EMT) is recognized as a pivotal driver of fibroblast activation and extracellular matrix deposition. In this study, we aimed to develop low-molecular-weight dextran sulfate sodium (LMW-DSS) derivatives and assess their capacity to interfere with EMT, thereby offering novel therapeutic avenues for IPF management. Starting with dextran (2 kDa) as a precursor, we successfully synthesized two sulfated derivatives, DSS-LS and DSS-HS, via distinct sulfonation processes. Using a TGF-β1-stimulated A549 alveolar epithelial cell model, we demonstrated that LMW-DSS compounds exhibited no cytotoxicity, as validated by CCK-8 viability assays. Importantly, Transwell migration assays revealed that LMW-DSS markedly attenuated TGF-β1-induced A549 cell migration, indicating a potent anti-fibrotic effect. Moreover, qPCR and Western blotting analyses confirmed that LMW-DSS significantly suppressed the expression and secretion of key pro-fibrotic mediators, including TGF-β1 and VEGF-A, and downregulated critical EMT-associated markers such as Snail and vimentin. Notably, reduced α-SMA expression following LMW-DSS treatment further substantiated its role in hindering EMT progression. Collectively, these findings highlighted the capacity of LMW-DSS to effectively impede EMT and fibrotic processes, thereby delaying the progression of pulmonary fibrosis. This work not only underscored the therapeutic potential of LMW-DSS in IPF but also provided compelling experimental evidence to support its development as a promising anti-fibrotic agent for clinical application.

    Analysis of 979 cases of adverse drug reactions induced by antineoplastic drugs
    Xingnong Xu, Doudou He, Lei Ma
    2025, 34(3):  223-231.  DOI: 10.5246/jcps.2025.03.017
    Asbtract ( 7 )   HTML ( 1)  
    Figures and Tables | References | Related Articles | Metrics

    The aim of this study is to evaluate the characteristics and patterns of adverse drug reactions (ADRs) associated with antineoplastic drugs and provide insights for safer chemotherapy practices. Based on 979 ADR cases reported in our hospital from January 1, 2022, to December 31, 2023, an analysis was conducted. Statistical analysis of the data revealed that 72.73% of these ADR incidents occurred in a hospital setting. The incidence of ADRs was higher in female patients compared to males, with the majority of cases (59.14%) observed in individuals aged 51–70 years. Intravenous administration was the predominant route linked to ADRs, accounting for 69.66% of the cases. Serious ADRs represented 9.30% of the total, including one instance where symptoms did not improve despite drug discontinuation or treatment. Cytotoxic antineoplastic drugs were responsible for 97.85% of all ADRs, with oxaliplatin being the most frequently implicated agent (19.82%). Gastrointestinal system involvement was the most common ADR manifestation, observed in 60.79% of cases. These findings underscored the necessity of enhanced monitoring for ADRs associated with cytotoxic antineoplastic drugs, particularly platinum-based agents. Comprehensive risk assessments and tailored treatment plans should be implemented during chemotherapy to minimize the occurrence of ADRs and safeguard patient safety.